ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBladder cancer (BC) is a prevalent malignancy with high metastatic and recurrent potential. Filamin C (FLNC) has been reported implicated in various cancers, but its role in BC remains unclear.
methodsBioinformatics analysis using The gene expression profiling interactive analysis (GEPIA) and The cancer genome atlas (TCGA) databases assessed FLNC expression, prognosis, and multivariate Cox regression in bladder urothelial carcinoma (BLCA). Human protein atlas (HPA) database provided immunohistochemical images. In vitro, CCK-8, wound healing, Transwell, and western blotting (WB) assays evaluated BC cell proliferation, migration, invasion, epithelial‑mesenchymal transition (EMT), and MAPK/ERK signaling. Co‑immunoprecipitation and immunofluorescence examined FLNC‑MEK1/2 interaction and co‑localization. Rescue experiments used the MEK agonist C16‑PAF or inhibitor U0126. In vivo, the effects of FLNC on BC progression and lung metastasis were verified through nude mouse xenograft tumor models and lung metastasis models, with WB and immunohistochemistry detecting EMT and MAPK/ERK pathway proteins.
resultsFLNC was upregulated in different disease stages of BLCA and was associated with poor prognosis. In vitro, FLNC significantly promoted the proliferation, migration, and invasion abilities of BC cells and facilitated the EMT process. In vivo, FLNC promoted tumor growth, lung metastasis, and EMT. Mechanistically, FLNC directly interacted with MEK1/2 and co‑localized in the cytoplasm, activating the MAPK/ERK pathway. Rescue experiments showed that a MEK agonist reversed the effects of FLNC knockdown, while a MEK inhibitor reversed the effects of FLNC overexpression.
conclusionFLNC drives BC progression and metastasis via MAPK/ERK activation and EMT induction.
Indexed as
Identifiers
42301608What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.